| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Articles in PresS, published online ahead of print June 5, 2002
Am J Physiol Lung Cell Mol Physiol, 10.1152/ajplung.00061.2002
Submitted on February 15, 2002
Accepted on May 16, 2002
1 Medicine/Meakins-Christie Laboratories, McGill University, Montreal, Quebec, Canada
2 Genetics Unit, Shriners Hospital for Crippled Children, McGill University, Montreal, Quebec, Canada
* To whom correspondence should be addressed. E-mail: mara.ludwig{at}mcgill.ca.
Bleomycin (BM)-induced pulmonary fibrosis results in excess production of proteoglycans (PGs). Because transforming growth factor-ß1 (TGF-ß1) promotes fibrosis, and interferon- (IFN-) inhibits it, we hypothesized that TGF-ß1 treatment would upregulate PG production in fibrotic lung fibroblasts, and IFN- would abrogate this effect. Primary lung fibroblasts cultures were established from rats 14 days after saline (CON) or BM (1.5 U) injection. PGs were extracted and subject to Western blot analysis. Bleomycin-exposed lung fibroblasts (BLF) exhibited increased production of versican (VS), heparan sulfate proteoglycan (HSPG) and biglycan (BG) as compared to normal lung fibroblasts (NLF). Compared to NLF, BLF released significantly increased amounts of TGF-ß1. TGF-ß1 (5 ng/ml x 48 hr) upregulated PG expression in both BLF and NLF. Incubation of BLF with anti-TGF-ß antibody (1, 5, 10 µg/ml) inhibited PG expression in a dose-dependent manner. Treatment of BLF with IFN- (500 U/ml/48 h) reduced VS, HSPG and BG expression. Furthermore, IFN- inhibited TGF-ß1-induced increases in PG expression by these fibroblasts. Activation of fibroblasts by TGF-ß1 promotes abnormal deposition of PGs in fibrotic lungs; downregulation of TGF-ß1 by IFN- may have potential therapeutic benefits in this disease.
This article has been cited by other articles:
|
|
 |
|
  D. S. Faffe and W. A. Zin Lung Parenchymal Mechanics in Health and Disease Physiol Rev, July 1, 2009; 89(3): 759 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Kliment, J. M. Englert, B. R. Gochuico, G. Yu, N. Kaminski, I. Rosas, and T. D. Oury Oxidative Stress Alters Syndecan-1 Distribution in Lungs with Pulmonary Fibrosis J. Biol. Chem., February 6, 2009; 284(6): 3537 - 3545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Gonzalez, F. Le Bellego, and M. S. Ludwig Imbalance of Receptor-Regulated and Inhibitory Smads in Lung Fibroblasts from Bleomycin-Exposed Rats Am. J. Respir. Cell Mol. Biol., February 1, 2007; 36(2): 206 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A Pacanowski and G. W Amsden Interferon Gamma-1b in the Treatment of Idiopathic Pulmonary Fibrosis Ann. Pharmacother., October 1, 2005; 39(10): 1678 - 1686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Fust, F. LeBellego, R. V. Iozzo, P. J. Roughley, and M. S. Ludwig Alterations in lung mechanics in decorin-deficient mice Am J Physiol Lung Cell Mol Physiol, January 1, 2005; 288(1): L159 - L166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Venkatesan, L. Pini, and M. S. Ludwig Changes in Smad expression and subcellular localization in bleomycin-induced pulmonary fibrosis Am J Physiol Lung Cell Mol Physiol, December 1, 2004; 287(6): L1342 - L1347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Larsen, E. Tufvesson, J. Malmstrom, M. Morgelin, M. Wildt, A. Andersson, A. Lindstrom, A. Malmstrom, C.-G. Lofdahl, G. Marko-Varga, et al. Presence of Activated Mobile Fibroblasts in Bronchoalveolar Lavage from Patients with Mild Asthma Am. J. Respir. Crit. Care Med., November 15, 2004; 170(10): 1049 - 1056. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
